You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


RET Inhibitors for RET-Altered Non-Small Cell Lung Cancer: Identification, Treatment, and Practicalities 

  • Authors: Solange Peters, MD, PhD; Benjamin Besse, MD, PhD; Vivek Subbiah, MD
  • CME Released: 11/21/2022
  • Valid for credit through: 11/21/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US and non-UK oncology specialists, pulmonologists, and pathologists.

The goal of this activity is for learners to be better able to identify and manage patients with RET-altered non-small cell lung cancer (NSCLC).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Identification of RET fusion-positive NSCLC
    • Clinical data on RET inhibitors for RET-altered NSCLC
  • Have greater competence related to
    • Managing treatment-related adverse events associated with RET inhibitors
  • Demonstrate greater confidence in their ability to
    • Manage patients with RET-altered NSCLC in daily clinical practice


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Solange Peters, MD, PhD

    Professor of Oncology
    Medical Oncology Chair
    Lausanne University Hospital
    Lausanne, Switzerland


    Solange Peters, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Amgen; Arcus; AstraZeneca; Bayer; BeiGene; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo; Debiopharm; Eli Lilly and Company; F-Star Therapeutics; Fishawack; Foundation Medicine; Genzyme; Gilead Sciences; GlaxoSmithKline; Illumina; Imedex; IQVIA; Incyte; iTeos Therapeutics; Janssen; Merck Sharp and Dohme; Merck Serono; Merrimack; Novartis; Novocure; PharmaMar; Phosplatin Therapeutics; PER; Pfizer; Prime Therapeutics; Regeneron Pharmaceuticals; Roche/Genentech; RTP; Sanofi; Seagen Inc.; Takeda; Vaccibody
    Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly and Company; Foundation Medicine; Illumina; Imedex; Merck Sharp and Dohme; Mirati Therapeutics; Novartis; PER; Pfizer; Prime Therapeutics; Roche/Genentech; RTP; Sanofi; Takeda
    Research funding from: Amgen; AstraZeneca; BeiGene; Bristol Myers Squibb; GlaxoSmithKline; Merck Sharp and Dohme; Roche/Genentech

  • Benjamin Besse, MD, PhD

    Professor and Head, Clinical Research
    Gustave Roussy Cancer Center
    Chair, EORTC Scientific Chairs Council
    Villejuif, France


    Benjamin Besse, MD, PhD, has the following relevant financial relationships:
    Research funding from: 4D Pharma; AbbVie; Amgen; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Celgene; Cergentis; Chugai Pharmaceutical; Cristal Therapeutics; Daiichi Sankyo; Eli Lilly and Company; Eisai; Genzyme Corporation; GlaxoSmithKline; Inivata; Ipsen; Janssen; Onxeo; OSE Immunotherapeutics; Pfizer; Roche/Genentech; Sanofi; Takeda; Tolero Pharmaceuticals; Turning Point Therapeutics

  • Vivek Subbiah, MD

    Associate Professor
    Department of Investigational Cancer Therapeutics
    Division of Cancer Medicine
    Executive Director
    Medical Oncology Research
    MD Anderson Cancer Network
    Center Clinical Medical Director
    Clinical Center for Targeted Therapy
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States


    Vivek Subbiah, MD, has the following relevant financial relationships:
    Consultant or advisor for: Daiichi Sankyo; Helsinn Healthcare; Incyte Corporation; Jazz Pharmaceuticals; Loxo Oncology/Eli Lilly and Company; MedImmune; Novartis; QED Therapeutics; R-Pharm US; Relay Therapeutics
    Research funding from: AbbVie; Agensys, Inc.; Alfasigma; Altum; Amgen; Bayer; BERG Health; Blueprint Medicines; Boston Biomedical, Inc.; Boston Pharmaceuticals; Celgene Corporation; D3 Bio, Inc.; Dragonfly Therapeutics, Inc.; Exelixis; Fujifilm; GlaxoSmithKline; Idera Pharmaceuticals, Inc.; Incyte Corporation; Inhibrx; Loxo Oncology; MedImmune; MultiVir, Inc.; NanoCarrier, Co.; Northwest Biotherapeutics; Novartis; PharmaMar; Pfizer; Relay Therapeutics; Roche/Genentech; Takeda; Turning Point Therapeutics; Vegenics Pty Ltd.
    Other: Travel support from: Helsinn Healthcare; Incyte Corporation; Novartis; PharmaMar


  • Megan Cannon, PhD

    Medical Education Director, WebMD Global, LLC


    Megan Cannon, PhD, has no relevant financial relationships.

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC


    Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


RET Inhibitors for RET-Altered Non-Small Cell Lung Cancer: Identification, Treatment, and Practicalities 

Authors: Solange Peters, MD, PhD; Benjamin Besse, MD, PhD; Vivek Subbiah, MDFaculty and Disclosures

CME Released: 11/21/2022

Valid for credit through: 11/21/2023


Contents of This CME Activity

All sections of this activity are required for credit.

Identifying RET-Altered NSCLC: Why and When?

In this video, Dr Peters addresses key questions around RET fusions and adopting comprehensive genomic profiling in clinical practice.
Solange Peters, MD, PhD

RET Inhibitors: Review of the Evidence

Dr Besse recaps the latest clinical evidence for the treatment of RET-altered NSCLC and provides expert insights on the implications of the data.
Benjamin Besse, MD, PhD

RET Inhibitors: Practical Considerations

Dr Besse and Dr Subbiah share best practices for managing treatment-related adverse events with RET inhibitor therapy.
Benjamin Besse, MD, PhD; Vivek Subbiah, MD

Summary and Key Takeaways

Join Dr Peters for a summary and key take-home messages from the program.
Solange Peters, MD, PhD

Educational Impact Challenge

The goal of this activity is for learners to be better able to identify and manage patients with RET-altered non-small cell lung cancer (NSCLC).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print